Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in allogeneic hematopoietic stem cell transplant recipients
2009-012087-13Phase 3Completed
- Sponsor
- Pfizer
- Start
- Sep 2009
- Modality
- Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pneumococcal 13-valent conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal disease, sponsored by Pfizer. Primary endpoint: Serotype-specific mean IgG fold rise after 3 doses of 13vPnC. Started Sep 2009; status: completed.
02
Drugs
pneumococcal 13-valent conjugate vaccine23-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2009-012087-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012087-13.